331 related articles for article (PubMed ID: 31319973)
21. The role of circulating tumor cells in evaluation of prognosis and treatment response in advanced non-small-cell lung cancer.
Zhou J; Dong F; Cui F; Xu R; Tang X
Cancer Chemother Pharmacol; 2017 Apr; 79(4):825-833. PubMed ID: 28289866
[TBL] [Abstract][Full Text] [Related]
22. Dynamic Monitoring and Predictive Value of Circulating Tumor Cells in EGFR-Mutated Advanced Non-Small-Cell Lung Cancer Patients Treated With First-Line EGFR Tyrosine Kinase Inhibitors.
Jiang T; Zhao J; Zhao C; Li X; Shen J; Zhou J; Ren S; Su C; Zhou C; O'Brien M
Clin Lung Cancer; 2019 Mar; 20(2):124-133.e2. PubMed ID: 30587399
[TBL] [Abstract][Full Text] [Related]
23. Circulating tumor cells in pulmonary vein and peripheral arterial provide a metric for PD-L1 diagnosis and prognosis of patients with non-small cell lung cancer.
Dong J; Zhu D; Tang X; Lu D; Qiu X; Li B; Lin D; Li L; Liu J; Zhou Q
PLoS One; 2019; 14(7):e0220306. PubMed ID: 31348821
[TBL] [Abstract][Full Text] [Related]
24. PD-L1 expression in circulating tumor cells of advanced non-small cell lung cancer patients treated with nivolumab.
Guibert N; Delaunay M; Lusque A; Boubekeur N; Rouquette I; Clermont E; Mourlanette J; Gouin S; Dormoy I; Favre G; Mazieres J; Pradines A
Lung Cancer; 2018 Jun; 120():108-112. PubMed ID: 29748004
[TBL] [Abstract][Full Text] [Related]
25. High Specificity in Circulating Tumor Cell Identification Is Required for Accurate Evaluation of Programmed Death-Ligand 1.
Schehr JL; Schultz ZD; Warrick JW; Guckenberger DJ; Pezzi HM; Sperger JM; Heninger E; Saeed A; Leal T; Mattox K; Traynor AM; Campbell TC; Berry SM; Beebe DJ; Lang JM
PLoS One; 2016; 11(7):e0159397. PubMed ID: 27459545
[TBL] [Abstract][Full Text] [Related]
26. Sensitive detection of viable circulating tumor cells using a novel conditionally telomerase-selective replicating adenovirus in non-small cell lung cancer patients.
Togo S; Katagiri N; Namba Y; Tulafu M; Nagahama K; Kadoya K; Takamochi K; Oh S; Suzuki K; Sakurai F; Mizuguchi H; Urata Y; Takahashi K
Oncotarget; 2017 May; 8(21):34884-34895. PubMed ID: 28432274
[TBL] [Abstract][Full Text] [Related]
27. Association of circulating tumour cells with early relapse and 18F-fluorodeoxyglucose positron emission tomography uptake in resected non-small-cell lung cancers.
Bayarri-Lara CI; de Miguel Pérez D; Cueto Ladrón de Guevara A; Rodriguez Fernández A; Puche JL; Sánchez-Palencia Ramos A; Ruiz Zafra J; Giraldo Ospina CF; Delgado-Rodríguez M; Expósito Ruiz M; Moyano Rodriguez MJ; Lorente JA; Serrano MJ
Eur J Cardiothorac Surg; 2017 Jul; 52(1):55-62. PubMed ID: 28369376
[TBL] [Abstract][Full Text] [Related]
28. Quantification of rare circulating tumor cells in non-small cell lung cancer by ligand-targeted PCR.
Lou J; Ben S; Yang G; Liang X; Wang X; Ni S; Han B
PLoS One; 2013; 8(12):e80458. PubMed ID: 24324600
[TBL] [Abstract][Full Text] [Related]
29. Tracking viable circulating tumor cells (CTCs) in the peripheral blood of non-small cell lung cancer (NSCLC) patients undergoing definitive radiation therapy: pilot study results.
Dorsey JF; Kao GD; MacArthur KM; Ju M; Steinmetz D; Wileyto EP; Simone CB; Hahn SM
Cancer; 2015 Jan; 121(1):139-49. PubMed ID: 25241991
[TBL] [Abstract][Full Text] [Related]
30. Prevalence and number of circulating tumour cells and microemboli at diagnosis of advanced NSCLC.
Mascalchi M; Falchini M; Maddau C; Salvianti F; Nistri M; Bertelli E; Sali L; Zuccherelli S; Vella A; Matucci M; Voltolini L; Pegna AL; Luconi M; Pinzani P; Pazzagli M
J Cancer Res Clin Oncol; 2016 Jan; 142(1):195-200. PubMed ID: 26210156
[TBL] [Abstract][Full Text] [Related]
31. Circulating tumor cell as a biomarker for evaluating allogenic NK cell immunotherapy on stage IV non-small cell lung cancer.
Lin M; Liang SZ; Shi J; Niu LZ; Chen JB; Zhang MJ; Xu KC
Immunol Lett; 2017 Nov; 191():10-15. PubMed ID: 28916277
[TBL] [Abstract][Full Text] [Related]
32. Tumour-associated circulating microparticles: A novel liquid biopsy tool for screening and therapy monitoring of colorectal carcinoma and other epithelial neoplasia.
Willms A; Müller C; Julich H; Klein N; Schwab R; Güsgen C; Richardsen I; Schaaf S; Krawczyk M; Krawczyk M; Lammert F; Schuppan D; Lukacs-Kornek V; Kornek M
Oncotarget; 2016 May; 7(21):30867-75. PubMed ID: 27127176
[TBL] [Abstract][Full Text] [Related]
33. Peripheral arterial disease and systematic detection of circulating tumor cells: rationale and design of the DETECTOR prospective cohort study.
Yannoutsos A; Fontaine M; Galloula A; Damotte D; Chatellier G; Paterlini-Bréchot P; Meyer G; Pastre J; Duchatelle V; Marini V; Schwering KL; Lazareth I; Ghaffari P; Stansal A; Sanson H; Labrousse C; Beaussier H; Nasr NB; Zins M; Salmeron S; Messas E; Lajonchère JP; Emmerich J; Priollet P; Trédaniel J
BMC Cardiovasc Disord; 2019 Sep; 19(1):212. PubMed ID: 31519196
[TBL] [Abstract][Full Text] [Related]
34. Detection of CTCs and CSCs in the staging and metastasis of non-small cell lung cancer based on microfluidic chip and the diagnostic significance.
Wang SQ; Shuai ZF; Zhang XJ; Wu T; Dong HY; Liu T; Wen QT; Yu XW
Eur Rev Med Pharmacol Sci; 2020 Sep; 24(18):9487-9496. PubMed ID: 33015791
[TBL] [Abstract][Full Text] [Related]
35. Characterization of DLL3-positive circulating tumor cells (CTCs) in patients with small cell lung cancer (SCLC) and evaluation of their clinical relevance during front-line treatment.
Messaritakis I; Nikolaou M; Koinis F; Politaki E; Koutsopoulos A; Lagoudaki E; Vetsika EK; Georgoulias V; Kotsakis A
Lung Cancer; 2019 Sep; 135():33-39. PubMed ID: 31447000
[TBL] [Abstract][Full Text] [Related]
36. Circulating Tumor Cells Enriched by the Depletion of Leukocytes with Bi-Antibodies in Non-Small Cell Lung Cancer: Potential Clinical Application.
Yin J; Wang Y; Yin H; Chen W; Jin G; Ma H; Dai J; Chen J; Jiang Y; Wang H; Liu Z; Hu Z; Shen H
PLoS One; 2015; 10(8):e0137076. PubMed ID: 26317979
[TBL] [Abstract][Full Text] [Related]
37. EGFR and HER3 expression in circulating tumor cells and tumor tissue from non-small cell lung cancer patients.
Scharpenseel H; Hanssen A; Loges S; Mohme M; Bernreuther C; Peine S; Lamszus K; Goy Y; Petersen C; Westphal M; Glatzel M; Riethdorf S; Pantel K; Wikman H
Sci Rep; 2019 May; 9(1):7406. PubMed ID: 31092882
[TBL] [Abstract][Full Text] [Related]
38. The application of nano-enrichment in CTC detection and the clinical significance of CTCs in non-small cell lung cancer (NSCLC) treatment.
Wei T; Zhu D; Yang Y; Yuan G; Xie H; Shen R
PLoS One; 2019; 14(7):e0219129. PubMed ID: 31344053
[TBL] [Abstract][Full Text] [Related]
39. High-Throughput Label-Free Isolation of Heterogeneous Circulating Tumor Cells and CTC Clusters from Non-Small-Cell Lung Cancer Patients.
Zeinali M; Lee M; Nadhan A; Mathur A; Hedman C; Lin E; Harouaka R; Wicha MS; Zhao L; Palanisamy N; Hafner M; Reddy R; Kalemkerian GP; Schneider BJ; Hassan KA; Ramnath N; Nagrath S
Cancers (Basel); 2020 Jan; 12(1):. PubMed ID: 31947893
[TBL] [Abstract][Full Text] [Related]
40. CD47 Expression in Circulating Tumor Cells and Circulating Tumor Microemboli from Non-Small Cell Lung Cancer Patients Is a Poor Prognosis Factor.
Torres JA; Brito ABC; Silva VSE; Messias IM; Braun AC; Ruano APC; Buim MEC; Carraro DM; Chinen LTD
Int J Mol Sci; 2023 Jul; 24(15):. PubMed ID: 37569332
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
